GSA Capital Partners LLP Decreases Stake in Sutro Biopharma, Inc. $STRO

GSA Capital Partners LLP reduced its position in Sutro Biopharma, Inc. (NASDAQ:STRO) by 49.1% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 89,067 shares of the company’s stock after selling 85,776 shares during the period. GSA Capital Partners LLP’s holdings in Sutro Biopharma were worth $1,031,000 at the end of the most recent quarter.

A number of other hedge funds also recently made changes to their positions in the company. Jacobs Levy Equity Management Inc. purchased a new stake in shares of Sutro Biopharma in the third quarter worth about $387,000. Velan Capital Investment Management LP increased its stake in Sutro Biopharma by 2.0% during the third quarter. Velan Capital Investment Management LP now owns 3,120,000 shares of the company’s stock worth $2,709,000 after acquiring an additional 60,000 shares during the last quarter. Bank of America Corp DE increased its stake in Sutro Biopharma by 51.3% during the third quarter. Bank of America Corp DE now owns 119,434 shares of the company’s stock worth $104,000 after acquiring an additional 40,488 shares during the last quarter. Shay Capital LLC increased its stake in Sutro Biopharma by 20.1% during the third quarter. Shay Capital LLC now owns 312,051 shares of the company’s stock worth $271,000 after acquiring an additional 52,162 shares during the last quarter. Finally, Two Sigma Investments LP increased its stake in Sutro Biopharma by 244.8% during the third quarter. Two Sigma Investments LP now owns 396,785 shares of the company’s stock worth $345,000 after acquiring an additional 281,717 shares during the last quarter. 96.99% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Sutro Biopharma in a research note on Friday, May 8th. Citigroup reissued an “outperform” rating on shares of Sutro Biopharma in a research note on Friday, April 17th. Leerink Partners set a $43.00 price objective on Sutro Biopharma and gave the stock an “outperform” rating in a research note on Friday, May 15th. Lifesci Capital raised Sutro Biopharma to a “strong-buy” rating in a research note on Friday, May 1st. Finally, Citizens Jmp boosted their price objective on Sutro Biopharma from $35.00 to $41.00 and gave the stock a “market outperform” rating in a research note on Thursday, April 23rd. Three investment analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Sutro Biopharma presently has an average rating of “Buy” and a consensus price target of $48.25.

Sutro Biopharma Stock Performance

STRO opened at $30.62 on Friday. The stock has a market cap of $507.37 million, a price-to-earnings ratio of -2.77 and a beta of 1.63. The stock’s 50 day moving average price is $29.79 and its 200-day moving average price is $18.92. Sutro Biopharma, Inc. has a one year low of $6.74 and a one year high of $43.85.

Sutro Biopharma (NASDAQ:STRO) last released its earnings results on Thursday, May 14th. The company reported ($2.94) EPS for the quarter, missing analysts’ consensus estimates of ($2.74) by ($0.20). The firm had revenue of $14.52 million during the quarter, compared to analysts’ expectations of $8.89 million. As a group, analysts predict that Sutro Biopharma, Inc. will post -9 earnings per share for the current fiscal year.

Sutro Biopharma Profile

Sutro Biopharma, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel biologic drug candidates in the fields of oncology and immunology. The company leverages a proprietary cell-free protein synthesis platform, XpressCF™, to design and produce complex, multi-specific proteins that include antibody-drug conjugates, bispecific antibodies, and cytokine fusion proteins. This platform enables rapid generation and optimization of protein therapeutics that may not be feasible with traditional cell-based expression systems.

Founded in 2003 and headquartered in South San Francisco, California, Sutro Biopharma has built a pipeline of immuno-oncology candidates in various stages of preclinical and clinical development.